Plain-English translation of NCT06170970 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Multiple Sclerosis research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing , a medication that promotes wakefulness, to see if it can help reduce fatigue and excessive daytime sleepiness in people with multiple sclerosis. Fatigue affects up to 90% of MS patients and can be severely disabling, but current treatments haven't worked well for many people. This study will measure whether the medication is more effective than a placebo at improving fatigue and daytime alertness.
Fatigue is one of the most common and troubling symptoms for people with MS, but available treatments have had limited success. Researchers believe this medication may work better specifically for MS patients who also struggle with excessive daytime sleepiness, and this trial will test that hypothesis.
You likely qualify if…
You likely don't qualify if…
You would first have a 10-day lead-in period with the study medication or placebo to see how you tolerate it. Then you'd enter two four-week treatment periods: you'd take either the medication or placebo for four weeks, have a one-week break, and then take whichever treatment you didn't get first for another four weeks. Throughout the study, you'd complete fatigue questionnaires and use a smartphone app that measures fatigue through typing patterns to give researchers real-time data. The total study lasts about 9 weeks.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
United States